Dysbetalipoproteinaemia - Clinical and pathophysiological features

South African Medical Journal

Volumn 92, Issue 11, 2002, Pages 892-897

  Blom, D J ^a   Byrnes, P ^a   Jones, S ^a   Marais, A D ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN E2; ARGININE; CYSTEINE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NICOTINIC ACID; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; DYSLIPIDEMIA; FEMALE; GENE MUTATION; HOMOZYGOSITY; HOMOZYGOTE; HUMAN; HYPERLIPOPROTEINEMIA TYPE 2; HYPERLIPOPROTEINEMIA TYPE 3; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PATHOPHYSIOLOGY; PERIPHERAL VASCULAR DISEASE; RETROSPECTIVE STUDY; SOUTH AFRICA; TRIACYLGLYCEROL BLOOD LEVEL; XANTHOMA;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; APOLIPOPROTEIN E2; APOLIPOPROTEINS E; CHILD; CHOLESTEROL, VLDL; DIAGNOSIS, DIFFERENTIAL; DNA MUTATIONAL ANALYSIS; FEMALE; HOMOZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE III; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 0036857850     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-126.
2. South African Medical Association and Lipid and Atherosclerosis Society of Southern Africa Working Group. Diagnosis, management and prevention of the common dyslipidaemia in South Africa - Clinical guideline, 2000. S Afr Med J 2000; 90: 164-174, 176-178.
3. Mahley RW, Rall S. Type III hyperlipoproteinemia (Dysbetalipoproteinaemia): The role of apolipoprotein E in normal and abnormal lipoprotein metabolism. In: Scriver A, Beadet W, Sly S, Valle D, eds. The Metabolic and Molecular Basis of Inherited Disease. New York: McGraw Hill, 2000: 1953-1980.
4. Mahley RW. Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology. Science 1988; 240: 622-630.
5. Mahley RW, Huang Y, Rall S. Pathogenis of type III hyperlipoproteinemia (dysbetalipoproteinemia): questions, quandaries and paradoxes. J Lipid Res 1999; 40: 1933-1949.
6. Mahley RW, Ji Z. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J Lipid Res. 1999; 40: 1-16.
7. Utermann G, Vogelberg KH, Steinmetz A, et al. Polymorphisms of apolipoprotein E. Genetics of hyperlipoproteinemia type III. Clin Genet 1979; 15: 37-62.
8. Utermann G, Steinmetz A, Weber W. Genetic control of human apolipoprotein E polymorphism: comparison of one- and two-dimensional techniques of isoprotein analysis. Human Genet 1982; 60: 344-351.
9. Weisgraber KH, Innerarity T, Mahley RW. Abnormal lipoprotein-receptor binding activity of the human E apoprotein due to cysteine-arginine interchange at a single site. J Biol Chem 1982; 257: 2518-2521.
10. Chait A, Abers J, Brunzell J, Hazzard W. Type-III hyperlipoproteinaemia ('Remnant Removal Disease'). Lancet 1977; 1: 1176-1178.
11. Huang Y, Liu X, Rall S, et al. Overexpression and accumulation of apolipoprotein E as a cause of hypertriglyceridemia. J Biol Chem 1998; 273: 26388-26393.
12. Huang Y, Liu X, Rall S, Mahley RW. Apolipoprotein E2 reduces the low density lipoprotein level in transgenic mice by impairing lipoprotein lipase-mediated lipolysis of triglycerideric lipoproteins. J Biol Chem 1998; 273: 17483-17490.
13. Thuren T, Wilcox R, Sisso, P, Waite, M. Hepatic lipase hydrolysis of lipid monolayers. J Biol Chem 1991; 266: 4853-4861.
14. Salah D, Bohnet K, Gueguen R, Siest G, Visvikis S. Combined effects of lipoprotein lipase and apolipoprotein E polymorphisms on lipid and lipoprotein levels in the Stanislas cohort. J Lipid Res 1997; 38: 904-912.
15. Masket, BH, Levy R, Fredrickson DS. The use of polyacrylamide gel electrophoresis in differentiating Type III hyperlipoproteinemia. J Lab Clin Med 1973; 81: 794-802.
16. Hazzard W, Porte DJ, Bierman EL. Abnormal lipid composition of very low density lipoproteins in diagnosis of broad-beta disease (type III hyperlipoproteinemia). Metabolism 1972; 21: 1009-1019.
17. Mishkel MA, Nazir DJ, Crowther SA. Longitudinal assessment of lipid ratios in the diagnosis of type III hyperlipoproteinaemia. Clin Chim Acta 1975; 58: 21-136.
18. Fredrickson DS, Morganroth J, Levy R. Type III hyperlipoproteinemia; an analysis of two contemporary definitions. Ann Intern Med 1975; 82: 150-157.
19. Albers JJ, Warnick RG, Hazzard W. Type III hyperlipoproteinemia: A comparative study of current diagnostic techniques. Clin Chim Acta 1977; 75: 193-204.
20. Hixson JE, Vernier DT. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with Hhal. J Lipid Res 1990; 31: 545-548.
21. Zannis VI, Breslow JL, Utermann G, et al. Proposed nomenclature of apoE isoproteins, apoE genotypes, and phenotypes. J Lipid Res 1982; 23: 911-914.
22. de Villiers WJS, van der Westhuyzen DR, Coetzee GA, Henderson HE, Marais AD. The apolipoprotein E2 (Arg145Cys) mutation causes autosomal dominant type III hyperlipoproteinemia with incomplete penetrance. Arterioscler Throm Vasc Biol 1997; 17: 865-872.
23. Brewer H, Zech L, Gregg R, Schwartz D, Schaefer E. Type III hyperlipoproteinemia: Diagnosis, molecular defects, pathology and treatment. Ann Intern Med 1983; 98: 623-640.
24. Morganroth J, Levy R, Fredrickson DS. The biochemical, clinical, and genetic features of type III hyperlipoproteinemia. Ann Intern Med 1975; 82: 158-174.
25. Borrie P. Type III hyperlipoproteinaemia. BMJ 1969; 2: 665-667.
26. Stuyt PM, Van t' Laar A. Clinical features of type III hyperlipoproteinaemia. Neth J Med 1983; 26: 104-111.
27. Heiberg A, Slack J. Family similarities in the age at coronary death in familial hypercholesterolaemia. BMJ, 1977; 2: 493-495.
28. Civeira F, Pocovi M, Cenarro A, et al. ApoE variants in patients with type III hyperlipoproteinemia. Atherosclerosis 1996; 127: 273-282.
29. Knijff P, van den Maagdenberg J, Stalenhoef A, et al. Familial dysbetalipoproteinemia with apolipoprotein E3-Leiden in an extended multigeneration pedigree. J Clin Invest 1991; 88: 643-655.
30. Civeira F, Cenarro A, Ferrando J, et al. Comparison of the hypolipidemic effect of gemfibrozil versus simvastatin in patients with type III hyperlipoproteinemia. Am Heart J 1999; 138: 156-162.